Completed Cancer NIHR-supported project Infection & Immunity
An open label Phase I/IIa clinical trial to assess the safety, immunogenicity and efficacy of the blood-stage malaria vaccine candidates R78C and RH5.1 in Matrix-M
About this grant
This summary is based on the grant title only — the full abstract was not available.
No substantive source abstract was published for this research project funded by NIHR.
Researchers
Angela Minassian (Principal Investigator)
Related Research
Grants with similar aims, by meaning.
An open label Phase I/IIa clinical trial to assess the safety, immunogenicity and efficacy of the malaria vaccine candidate RH5.2-virus-like particle (VLP) in Matrix-MTM, and to compare the safety and immunogenicity of the malaria vaccine candidates RH5.2-VLP in Matrix-MTM and RH5.1 soluble protein in Matrix-MTM used in various regimens
A Phase Ia clinical trial to assess the safety and immunogenicity of the blood-stage malaria candidate vaccines RH5.1 in Matrix-MTM and R78C in Matrix-MTM, both alone and in combination, in healthy UK adults
Phase I clinical trial to assess the safety and immunogenicity of the malaria vaccine candidate RH5.1 soluble protein in Matrix-MTM using two dosing regimens
Phase I clinical trial to assess the safety and immunogenicity of the malaria vaccine candidates RH5.2 virus-like particle (VLP) with Matrix-M, alone or together with RH5.1 soluble protein with Matrix-M
A Phase Ia clinical trial to assess the safety and immunogenicity of the pre-erythrocytic malaria candidate vaccines Rvx21 in Matrix-MTM and Rvx21 in combination with R21 in Matrix-MTM, in healthy malaria-naïve UK adults
Original classification
Life-saving VaccinesPlain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know